BIO.ASX: Quarterly Activities & Cashflow Report

Quarterly Activities & Cashflow Report

Stock	Biome Australia Ltd (BIO.ASX)
Release Time	29 Jul 2026, 8:40 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Biome Australia Reports Record Annual Sales and Consumer Sell-Through

Key Points

Record annual sales revenue of $23.9m in FY26, up 30% from FY25
Consumer sell-through of Activated Probiotics surpassed 100,000 units in June 2026
Biome Daily is now the number one probiotic product in Australian pharmacy
Signed a binding manufacturing agreement with Specialty Probiotics Australia

Full Summary

Biome Australia Limited (ASX: BIO) reported a record year in FY26, achieving annual sales revenue of $23.9 million, a 30% increase from FY25. The company also marked a milestone with consumer sell-through of Activated Probiotics surpassing 100,000 units in June 2026. Biome Daily, the company's flagship product, is now the number one probiotic in Australian pharmacies, both in units and dollar value. Additionally, Biome signed a binding manufacturing agreement with Specialty Probiotics Australia to bring the Activated Probiotics range onshore starting September 2026, with no capital investment required.

Outlook

Biome expects 1H FY27 to be its highest revenue-generating half-year on record, supported by new product launches and continued growth in international markets.